Wednesday, July 2, 2025 7/2/2025

Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease

Award Number: R01HL165169
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease - Project Summary RBC alloimmunization in patients with sickle cell disease (SCD) can lead to potentially fatal hemolytic events. Patients with SCD have the highest incidence of RBC alloimmunization, compared to all other disease populations including those with similar transfusion burdens. Factors explaining this high incidence are poorly understood. Identifying such factors would allow for identification of patients with SCD who may benefit from personalized transfusion protocols and rare antigen-matched units. Inflammation in the transfusion recipient has been shown to promote RBC alloantibody responses. We previously reported that proinflammatory type 1 interferons (IFNα/β) induced by viral infection or autoimmunity promote RBC alloimmunization in pre-clinical transfusion models. Recent studies, including preliminary data included in this application, have revealed that many patients with SCD have an IFNα/β gene signature, defined by leukocyte expression of IFNα/β stimulated genes. However, mechanisms leading to IFNα/β activation, including signaling pathways, receptors, and ligands, are poorly understood. Nearly all IFNα/β-inducing receptors are intracellular receptors for nucleic acids. Thus, phagocytosis of nucleic acid containing cells, including reticulocytes which are elevated in SCD, has the potential to activate IFNα/β pathways. Anti-RBC autoantibodies facilitate erythrophagocytosis, with alloimmunized patients with SCD having an increased incidence of such autoantibodies. While the RBC alloantibody/RBC autoantibody association is poorly understood, our preliminary data indicate that reticulocyte counts correlate with IFNα/β gene scores and erythrophagocytosis of autoantibody-opsonized reticulocytes from patients with SCD induces IFNα/β activation in human macrophages. Preliminary data also show that anti-RBC autoantibodies induce IFNα/β activation and RBC alloimmunization in a pre-clinical transfusion model. In this proposal, we aim to test the hypothesis that RBC autoantibodies promote IFNα/β-mediated RBC alloimmunization in SCD by identifying inflammatory pathways that induce IFNα/β (Aim 1) and determining the effects of autoantibody-induced IFNα/β inflammation on RBC alloimmunization in SCD mice (Aim 2). In Aim 1, IFNα/β pathways induced by autoantibodies will be identified in co-cultures of human macrophages and reticulocytes from patients with and without SCD, and the extension of findings will be tested in pre-clinical murine models. Identified pathways and receptors will inform ligands that induce IFNα/β in SCD. Aim 2 represents the first investigation of IFNα/β-regulated RBC alloimmunization in pre-clinical models of SCD and has the potential to reveal a mechanism that may contribute to the elevated incidence of RBC alloimmunization. Long term goals of this project include improved understanding of proinflammatory interferons in SCD, with the possibility that targeted IFNα/β-modulated therapy may be beneficial. Findings may also have applicability beyond SCD, with inflammatory interferons playing a critical role in autoimmunity and other disease processes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $417,500 )
2025	2025	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Blood Diseases and Resources Research	000	4	6/27/2025	NON-COMPETING CONTINUATION	$417,500
														Subtotal = $417,500

Issue Date FY: 2024 ( Subtotal = $417,500 )
2024	2024	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Blood Diseases and Resources Research	000	3	6/20/2024	NON-COMPETING CONTINUATION	$417,500
														Subtotal = $417,500

Issue Date FY: 2023 ( Subtotal = $417,500 )
2023	2023	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	WEST HOLLYWOOD	CA	90048	LOS ANGELES	USA	Blood Diseases and Resources Research	000	2	7/7/2023	NON-COMPETING CONTINUATION	$417,500
														Subtotal = $417,500

Issue Date FY: 2022 ( Subtotal = $417,500 )
2022	2022	CEDARS-SINAI MEDICAL CENTER	8700 BEVERLY BLVD	LOS ANGELES	CA	90048	LOS ANGELES	USA	Blood Diseases and Resources Research	000	1	6/10/2022	NEW	$417,500
														Subtotal = $417,500

Grand Total All Awards = $1,670,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease

Award Number: R01HL165169

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer